Grameen Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2015
NCT02509494
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

ad26.zebov (1 trial)

mva-bn-filo (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhagic Fever, Ebola (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2